These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 31961018)
1. Advances in histone demethylase KDM4 as cancer therapeutic targets. Lee DH; Kim GW; Jeon YH; Yoo J; Lee SW; Kwon SH FASEB J; 2020 Mar; 34(3):3461-3484. PubMed ID: 31961018 [TBL] [Abstract][Full Text] [Related]
2. KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells. Berry WL; Janknecht R Cancer Res; 2013 May; 73(10):2936-42. PubMed ID: 23644528 [TBL] [Abstract][Full Text] [Related]
3. KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review. Chin YW; Han SY Expert Opin Ther Pat; 2015 Feb; 25(2):135-44. PubMed ID: 25468267 [TBL] [Abstract][Full Text] [Related]
4. TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase. Chandhasin C; Dang V; Perabo F; Del Rosario J; Chen YK; Filvaroff E; Stafford JA; Clarke M Anticancer Drugs; 2023 Nov; 34(10):1122-1131. PubMed ID: 37067993 [TBL] [Abstract][Full Text] [Related]
5. KDM4 Demethylases: Structure, Function, and Inhibitors. Jiang Y; Liu L; Yang ZQ Adv Exp Med Biol; 2023; 1433():87-111. PubMed ID: 37751137 [TBL] [Abstract][Full Text] [Related]
6. Unravelling KDM4 histone demethylase inhibitors for cancer therapy. Baby S; Gurukkala Valapil D; Shankaraiah N Drug Discov Today; 2021 Aug; 26(8):1841-1856. PubMed ID: 34051367 [TBL] [Abstract][Full Text] [Related]
7. Recent Advances with KDM4 Inhibitors and Potential Applications. Wu Q; Young B; Wang Y; Davidoff AM; Rankovic Z; Yang J J Med Chem; 2022 Jul; 65(14):9564-9579. PubMed ID: 35838529 [TBL] [Abstract][Full Text] [Related]
8. Structural and evolutionary basis for the dual substrate selectivity of human KDM4 histone demethylase family. Hillringhaus L; Yue WW; Rose NR; Ng SS; Gileadi C; Loenarz C; Bello SH; Bray JE; Schofield CJ; Oppermann U J Biol Chem; 2011 Dec; 286(48):41616-41625. PubMed ID: 21914792 [TBL] [Abstract][Full Text] [Related]
9. Studies on the catalytic domains of multiple JmjC oxygenases using peptide substrates. Williams ST; Walport LJ; Hopkinson RJ; Madden SK; Chowdhury R; Schofield CJ; Kawamura A Epigenetics; 2014 Dec; 9(12):1596-603. PubMed ID: 25625844 [TBL] [Abstract][Full Text] [Related]
11. Mechanistic and structural studies of KDM-catalysed demethylation of histone 1 isotype 4 at lysine 26. Walport LJ; Hopkinson RJ; Chowdhury R; Zhang Y; Bonnici J; Schiller R; Kawamura A; Schofield CJ FEBS Lett; 2018 Oct; 592(19):3264-3273. PubMed ID: 30156264 [TBL] [Abstract][Full Text] [Related]
12. KDM4 inhibitor SD49-7 attenuates leukemia stem cell Li Y; Wang C; Gao H; Gu J; Zhang Y; Zhang Y; Xie M; Cheng X; Yang M; Zhang W; Li Y; He M; Xu H; Zhang H; Ji Q; Ma T; Ding S; Zhao Y; Gao Y Theranostics; 2022; 12(11):4922-4934. PubMed ID: 35836814 [No Abstract] [Full Text] [Related]
13. The oncogenic potential of Jumonji D2 (JMJD2/KDM4) histone demethylase overexpression. Young LC; Hendzel MJ Biochem Cell Biol; 2013 Dec; 91(6):369-77. PubMed ID: 24219278 [TBL] [Abstract][Full Text] [Related]
14. The role of the histone demethylase KDM4A in cancer. Guerra-Calderas L; González-Barrios R; Herrera LA; Cantú de León D; Soto-Reyes E Cancer Genet; 2015 May; 208(5):215-24. PubMed ID: 25633974 [TBL] [Abstract][Full Text] [Related]
15. Heme, A Metabolic Sensor, Directly Regulates the Activity of the KDM4 Histone Demethylase Family and Their Interactions with Partner Proteins. Konduri PC; Wang T; Salamat N; Zhang L Cells; 2020 Mar; 9(3):. PubMed ID: 32235736 [TBL] [Abstract][Full Text] [Related]
16. Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer. Ye Q; Holowatyj A; Wu J; Liu H; Zhang L; Suzuki T; Yang ZQ Am J Cancer Res; 2015; 5(4):1519-30. PubMed ID: 26101715 [TBL] [Abstract][Full Text] [Related]
17. Advances in Histone Demethylase KDM3A as a Cancer Therapeutic Target. Yoo J; Jeon YH; Cho HY; Lee SW; Kim GW; Lee DH; Kwon SH Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32354028 [TBL] [Abstract][Full Text] [Related]
18. C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays. Le Bihan YV; Lanigan RM; Atrash B; McLaughlin MG; Velupillai S; Malcolm AG; England KS; Ruda GF; Mok NY; Tumber A; Tomlin K; Saville H; Shehu E; McAndrew C; Carmichael L; Bennett JM; Jeganathan F; Eve P; Donovan A; Hayes A; Wood F; Raynaud FI; Fedorov O; Brennan PE; Burke R; van Montfort RLM; Rossanese OW; Blagg J; Bavetsias V Eur J Med Chem; 2019 Sep; 177():316-337. PubMed ID: 31158747 [TBL] [Abstract][Full Text] [Related]
19. Reader domain specificity and lysine demethylase-4 family function. Su Z; Wang F; Lee JH; Stephens KE; Papazyan R; Voronina E; Krautkramer KA; Raman A; Thorpe JJ; Boersma MD; Kuznetsov VI; Miller MD; Taverna SD; Phillips GN; Denu JM Nat Commun; 2016 Nov; 7():13387. PubMed ID: 27841353 [TBL] [Abstract][Full Text] [Related]
20. Heme promotes transcriptional and demethylase activities of Gis1, a member of the histone demethylase JMJD2/KDM4 family. Lal S; Comer JM; Konduri PC; Shah A; Wang T; Lewis A; Shoffner G; Guo F; Zhang L Nucleic Acids Res; 2018 Jan; 46(1):215-228. PubMed ID: 29126261 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]